The 4FRONT-1 Study

Status:

Sponsor: 4D Molecular Therapeutics

Trial Summary

A Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration.

4D-150 is currently being evaluated in the 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials and the ongoing Phase 1/2 PRISM clinical trial in adults with wet AMD. 4D-150 is also being evaluated in Part 1 of the SPECTRA clinical trial in adults with DME. We believe this product candidate is highly differentiated because it is designed as a single, routine, low-dose intravitreal injection with the potential to be a backbone therapy by inducing continuous expression of two therapeutic transgenes from retinal cells, resulting in durable suppression of four different vascular endothelial growth factor (VEGF) family members at the site of disease activity.

Condition(s) being studied:​

Exudative Macular Degeneration

Trial date:

Primary Completion (Estimated)

2027-11-29

Study Completion (Estimated)

2032-05-21

Explore Our Active Trials

  • The Izervay Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person’s central vision to worsen. Geographic atrophy is an…

  • The ASP7317 Study

    July 23, 2026

    Sponsor: Astellas Trial Summary Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina – the light-sensitive part at the back of the eye. There are 2 types of…

  • The EVOLVE Study

    July 23, 2026

    Sponsor: Astellas Trial Summary This study is focused on people with Stargardt disease (STGD) and STGD-like macular dystrophies, inherited retinal conditions that affect the macula and can lead to progressive loss of central vision. STGD is most commonly caused by changes in the ABCA4 gene, while STGD-like conditions are linked…

  • The SIENNA Study

    July 22, 2026

    Sponsor: REGENERON Trial Summary This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition…